Learn How Coenzyme Q10 Works in the Management of Congestive Heart Failure and How to Get the Most Bioavailable Form to the Patient. Kirk Hamilton interviews Peter H. Langsjoen, M.D., F.A.C.C. has been practicing cardiology since 1985. For the past 21 years he has worked exclusively as a non-invasive cardiologist, specializing in congestive heart failure, primary and statin-induced diastolic dysfunction, and other diseases of the heart muscle. Dr. Langsjoen has been involved with the clinical application of coenzyme Q10 (CoQ10) since 1983 when he began cooperating with his father, Per H. Langsjoen, M.D., F.A.C.C., who performed the first human double blind controlled heart failure study with CoQ10 in the United States. Over the past seven years Dr. Langsjoen and his wife Alena have established a research laboratory in Tyler, Texas, for the measurement of both reduced and oxidized CoQ10 in both plasma and tissue including the heart muscle.